Table 2. Treatment regimens Treatment .... | American Society of Hematology

Table 2.

Treatment regimens

Treatment	Early stage	Advanced stage
Active surveillance	23 (19)	14 (33)
Involved field RT	54 (45)	1 (2)
Extended field RT	20 (16)	0 (0)
Combined modality therapy	13 (11)	3 (7)
Combined modality therapy + rituximab*	3 (2)	0 (0)
CT	4 (3)	9 (22)
CT + rituximab*	2 (2)	11 (26)
Rituximab monotherapy†	2 (2)	4 (10)

Treatment	Early stage	Advanced stage
Active surveillance	23 (19)	14 (33)
Involved field RT	54 (45)	1 (2)
Extended field RT	20 (16)	0 (0)
Combined modality therapy	13 (11)	3 (7)
Combined modality therapy + rituximab*	3 (2)	0 (0)
CT	4 (3)	9 (22)
CT + rituximab*	2 (2)	11 (26)
Rituximab monotherapy†	2 (2)	4 (10)

Data are n (%).

Rituximab was given once per CT cycle.

†

Rituximab was given 4 times, once weekly, in all but 1 patient, who received 4 weekly doses of rituximab, followed by 2 years of maintenance treatment every 3 months.

View Large

This Feature Is Available To Subscribers Only